1-3 of 3
antisense oligonucleotide therapy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ILF2 Antisense Oligonucleotide Therapy and a CRISPR/Cas9-Based Screening for DNA Repair Effectors Identify Synthetic Lethal Approaches Enhancing Myeloma Cells Sensitivity to DNA Damage

Natthakan Thongon, PhD, Christopher Jackson, BS, Pamela Lockyer, MS, Jintan Liu, Andrea Santoni, PhD, Ashley Rose, BS, Guillermo Garcia-Manero, MD, Simona Colla, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 685.
https://doi.org/10.1182/blood-2019-129286
Published: 2019
Journal Articles

Developing a Galnac-Conjugated TMPRSS6 Antisense Therapy for the Treatment of β-Thalassemia

Mariam Aghajan, PhD, Carla Casu, PhD, Vania lo Presti, Sheri Booten, Brett P. Monia, PhD, Stefano Rivella, PhD, Shuling Guo, PhD
Journal: Blood
Blood (2016) 128 (22): 1013.
https://doi.org/10.1182/blood.V128.22.1013.1013
Published: 2016
Journal Articles

Induction of Endogenous Repair Mechanisms by Single-Stranded DNA Oligonucleotide Therapy for Correction of the DNA-PK Mutation in Murine Severe Combined Immune Deficiency.

Jakub Tolar, MD, PhD, Angela Panoskaltsis-Mortari, Ph.D., Anton K. Yerich, B.S., Ron T. McElmurry, B.S., Georg A. Hollander, Betsy T. Kren, Ph.D., Clifford J. Steer, M.D., Bruce R. Blazar, M.D.
Journal: Blood
Blood (2006) 108 (11): 454.
https://doi.org/10.1182/blood.V108.11.454.454
Published: 2006